Portal de Periódicos da CAPES

45P Analysis of lung cancer patient pathway: A 6-year nationwide analysis from Hungary

2021; Elsevier BV; Volume: 16; Issue: 4 Linguagem: Inglês

10.1016/s1556-0864(21)01887-6

1556-1380

Krisztina Bogos, G. Gaffly, Zoltán Kiss, Lilla Tamási, Gyula Ostoros, Veronika Müller, László Urbán, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Zoltán Polányi, Andrea R. Daniel, Balázs Nagy, György Rokszin, Zsolt Abonyi‐Tóth, Zsófia Barcza, Judit Moldvay, Zoltán Vokó,

Multiple and Secondary Primary Cancers

Background: This study aimed to examine the characteristics of the lung cancer (LC) patient pathway in Hungary during a 6-year period. Methods: Methods This nationwide, retrospective study included patients newly diagnosed with LC (ICD-10 C34) between January 1, 2011 and December 31, 2016 using data from the National Health Insurance Fund (NHIF) of Hungary. Following patient pathway intervals were examined: system-, diagnostic- and treatment interval by age, gender, tumor type, study year and first-line LC therapy. Results: Results During the 6-year study period, 17,386 patients had at least one type of imaging (X-ray or CT/MRI) prior to diagnosis. The median system interval was 64.5 days, and it was 5 days longer among women than in men (68.0 vs. 63.0 days). The median system interval difference in patients with adenocarcinoma (n = 7,474) compared to those with squamous cell carcinoma (n = 4,674): 70.4 days (IQR: 47–99) vs. 64.0 days (IQR: 42.5–94) was significantly longer by 6.4 days (p < 0.001), the shortest median system interval was recorded among patients diagnosed with small cell lung cancer (n = 2,353; median: 48.0 days IQR: 30–74). Patients who received surgery as first-line treatment had significantly longer median system intervals compared to those receiving chemotherapy (81.4 days vs. 62.0 days). The mean diagnostic imaging interval decreased by 3.43 days from 24.33 to 20.90 days (p < 0.001), on the other hand, the mean diagnostic biopsy interval increased by 3.31 days (p < 0.001), and the mean treatment interval also increased by 4.09 days (p < 0.001) during the 6-year study period. Conclusions: This nationwide retrospective study provides valuable insights into the characteristics of the lung cancer patient pathway in Hungary and its changes over a 6-year period. The length of the whole patient pathway was comparable to reports from other countries and showed a 4-day increase during the study period, mainly due to longer treatment intervals with more specific examinations. The detailed analysis of the patient pathway allowed for the detection of temporal trends as well as disparities among patient subgroups, highlighting that there is still room for improvement to optimize the timeliness of lung cancer care. Clinical trial identification: 10338-5/2019/EKU. Legal entity responsible for the study: MSD Pharma Hungary Ltd. Funding: MSD Pharma Hungary Ltd. Disclosure: Z. Kiss: Full/Part-time employment: MSD Pharma Hungary Ltd. A. Vastag: Full/Part-time employment: MSD Pharma Hungary Ltd.; Z. Polányi: Full/Part-time employment: MSD Pharma Hungary Ltd. A. Daniel: Full/Part-time employment: MSD Pharma Hungary Ltd. B. Nagy: Research grant/Funding (institution): MSD Pharma Hungary Ltd. G. Rokszin: Honoraria (self): MSD Pharma Hungary Ltd. Z. Abonyi-Tóth: Honoraria (self): MSD Pharma Hungary Ltd. Z. Barcza: Honoraria (self): MSD Pharma Hungary Ltd. Z. Vokó: Research grant/Funding (institution): MSD Pharma Hungary Ltd. All other authors have declared no conflicts of interest.